SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001390478-24-000005
Filing Date
2024-03-28
Accepted
2024-03-28 16:08:44
Documents
14
Period of Report
2024-03-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sls-20240328.htm   iXBRL 8-K 31703
2 EX-99.1 sls-202403288xkexhibit991.htm EX-99.1 87092
  Complete submission text file 0001390478-24-000005.txt   258688

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sls-20240328.xsd EX-101.SCH 1931
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sls-20240328_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sls-20240328_pre.xml EX-101.PRE 13067
17 EXTRACTED XBRL INSTANCE DOCUMENT sls-20240328_htm.xml XML 2826
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 24798927
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)